Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1α expression

Cancer Research

Volumn 59, Issue 5, 1999, Pages 1029-1035

  Voronov, Elena ^a   Weinstein, Yacob ^a   Benharroch, Daniel ^a   Cagnano, Emanuela ^a   Ofir, Rivka ^a   Dobkin, Maria ^a   White, Rosalyn M ^a   Zoller, Margot ^b   Barak, Vivian ^c   Segal, Shraga ^a   Apte, Ron N ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Hadasah University Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL COMPARTMENTALIZATION; GENE TRANSFER; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ANIMALS; CELL DIVISION; DEATH; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GROWTH INHIBITORS; IMMUNOTHERAPY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOKINES; LYMPHOMA, T-CELL; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PARALYSIS; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; SPINAL NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033106120     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Apte, R. N., Douvdevani, A., Zoller, M., White, R. M., Dvorkin, T., Shimoni, N., Fima, E., Hacham, M., Huleihel, M. Benharroch, D., Voronov, E., and Segal, S. Cytokine-induced tumor immunogenicity: interleukin-1α expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol. Lett., 39: 45-52, 1994.
2. Bubenik, J. Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther., 69: 1-14, 1996.
3. Davis, B. M., Koc, O. N., Lee, K., and Gerson, S. L. Current progress in the gene therapy of cancer. Curr. Opin. Oncol., 8: 499-508, 1996.
4. Dranoff, G., and Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol., 58: 417-454, 1995.
5. Forni, G., Cavallo, F., Consalvo, M., Allione, A., Dellabona, P., Casorati, G., and Giovarelli, M. Molecular approaches to cancer immunotherapy. Cytokines Mol. Ther., 1: 225-248, 1995.
6. Pardoll, D. M. Cancer vaccines: a road map for the next decade. Curr. Opin. Immunol., 8: 619-621, 1996.
7. Porgador, A., Tzehoval, H., Katz, A., Vadai, E., Revel, M., Feldman, M., and Eisenbach, L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res., 52: 3679-3686, 1992.
8. Qin, Z., and Blankenstein, T. Influence of local cytokines on tumor metastases: using cytokine gene-transfected tumor cells as experimental models. Curr. Top. Microhiol. Immunol. 213: 55-64, 1996.
9. Rosenberg, S. A. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu. Rev. Med., 41: 481-491, 1996.
10. Apte, R. N. Mechanisms of cytokine production by fibroblasts: implications for normal connective tissue homeostasis and pathological conditions. Folia Microbiol., 40: 392-404, 1995.
11. Colotta, F., Dower, S. K., Sims, J. E., and Mantovani, A. The type II "decoy" receptor: a novel regulatory pathway for interleukin 1. Immunol. Today, 15: 562-566, 1994.
12. Dayer, J-M., and Burger, D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur. Cytokine Netw., 5: 563-571, 1994.
13. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood, 87: 2095-2147, 1996.
14. Durum, S. K., and Oppenheim, J. J. Proinflammatory cytokines and immunity. In: W. E. Paul (ed.), Fundamental Immunology, Ed. 3, pp. 801-835. New York: Raven Press, Ltd., 1993.
15. Muegge, K., Williams, T. M., Kant, J., Karin, M., Chiu, R., Schmidt, A., Siebenlist, U., Young, H. A., and Durum, S. K. Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science (Washington DC), 246: 249-251, 1989.
16. Smith, K. A. Interleukin-2. Curr. Opin. Immunol., 4: 271-276, 1992.
17. Hornung, R. L., Kiertscher, S. M., and Mathews, H. L. Systemic IL-I and adjuvant treatment of an experimental tumor. Biotherapy, 5: 227-237, 1992.
18. Janik, J. E., Miller, L. L., Longo, D. L., Powers, G. C., Urba, W. J., Kopp, W. C., Gause, B. L., Curti, B. D., Fenton, R. G., Oppenheim, J. J., Conlon, K. C., Holmlund, J. T., Sznol, M., Sharfman, W. H., Steis, R. G., Creekmore, S. P., Alvord, W. G., and Beauchamp, A. E. Phase II trial of interleukin 1α and indomethacin in treatment of metastatic melanoma. J. Natl. Cancer Inst. (Bethesda), 88: 44-49, 1996.
19. Katsanis., E., Weisdorf, D. J., Xu, Z., Danciak, B. B., Halet, M. L., and Blaza, B. R. Infusions of interleukin 1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. Clin. Immunol., 14: 205-211, 1994.
20. Kiertscher, S. M., and Mathews, H. L. Systemic IL-1 and adjuvant treatment of an experimental tumor. Biotherapy, 5: 259-274, 1992.
21. North, R. J., Neubauer, R. H., Huang, J. J. H., Newton, R. C., and Loveless, S. E. Interleukin-1-induced. T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J. Exp. Med., 168: 2031-2043, 1988.
22. Salard, D., Kuzel, T. M., Samuelson, E., Rosen, S., and Bakouche, O. Interleukin-1α increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes. J. Clin. Immunol., 18: 223-226, 1998.
23. Smith, J, W., II. Urba, W. J., Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., Conlon, K. C., Sznol, M., Creekmore, S. P., Wells, N. ., Ruscetti, F. W., Keller, J. R., Hestdal, K., Shimizu, M., Rossio, J., and Alvord, W. G. The toxic and hematological effects of interleukin-1α administered in a Phase I trial to patients with advanced malignancies. J. Clin Oncol., 10: 1141-1152, 1992.
24. Tagliabue, A., and Boraschi, D. Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide. Vaccine, 11: 594-595, 1993.
25. Apte, R. N., Douvdevani, A., Zoller, M., White, R. M., Dvorkin, T., Shimoni, N., Huleihel, M., Fima, E., Hacham, M., Voronov, E., and Segal S. Involvement of immune responses in the eradication of IL-1α gene-transduced tumor cells: mechanisms of tumor rejection and immunotherapeutical implications. Folia Biol. Praha, 40: 1-18, 1994.
26. Douvdevani, A., Huleihel, M., Zoller, M., Segal, S., and Apte, R. N. Regulation of interleukin-1 generation in immune-activated fibroblasts. Eur. Cytokine Netw., 2: 257-264, 1991.
27. Douvdevani, A., Huleihel, M., Zoller, M., Segal, S., and Apte, R. N. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1α either spontaneously or following IL-1α gene transfer. Int. J. Cancer. 51: 822-830, 1992.
28. Zoller, M., Douvdevani, A., Segal, S., and Apte, R. N. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection. Int. J. Cancer, 50: 443-449, 1992.
29. Zoller, M, Douvdevani, A., Segal, S., and Apte, R. N. Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response. Int. J. Cancer, 50: 450-457, 1992.
30. Barak, V., Peritt, D., Flechner, I., Yanai, P., Treves, A., and Dinarello, C. A. The M 20 inhibitor is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res., 10: 437-442, 1991.
31. Peled, T., Rigel, M., Peritt, D., Treves, A. J., Fibach, E., and Barak, V. The effect of the M 20 IL-1 inhibitor on proliferation and differentiation of leukemic cells. Blood, 79: 1172-1177, 1992.
32. Zandman-Goddard, G., George, J., Blank, M., Levy, Y., Yanai, P., Halperin, T., Shoenfeld, Y., and Barak, V. The effects of early and late administration of M 20 derived IL-1 inhibitory on experimental systemic lupus erythematosus. Immunol. Lett., 53: 77-82, 1996.
33. Ofir, R., Gopas, J., Aflalo, E., and Weinstein, Y. Oligoclonality of Moloney leukemias. Leuk. Res., 16: 797-806, 1992.
34. Hansen, M. B., Nielsen, S. E., and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119: 203-210, 1989.
35. Cerdan, C., Martin, Y., Brailly, H., Courcoul, M., Flavetta, S., Costello, R., Mawas, C., Brig, F., and Olive, D. IL-1α is produced by T lymphocytes activated via the CD2 plus CD28 pathways. J. Immunol., 146: 560-564, 1991.
36. Tartakovsky, B., Finnegan, A., Muegge, K., Brody, D. T., Kovacs, E. J., Smith, M. R., Berzofsky, J. A., Young, H. A., and Durum, S. K. IL-1 is an autocrine growth factor for T cell clones. J. Immunol., 141: 3863-3867, 1988.
37. van-Kooten, C., Rensink, I., Pascual-Salcedo, D., van-Oers, R., and Aarden, L. Monokine production by human T cells: IL-1α production restricted to memory T cells. J. Immunol., 146: 2654-2658, 1991.